Brief: Aclaris Therapeutics Provides Corporate Update

Aclaris Therapeutics

19/12/2023 21:13

Dec 19 (Reuters) - Aclaris Therapeutics Inc  ACRS.O :
    * ACLARIS THERAPEUTICS PROVIDES CORPORATE UPDATE
    * ACLARIS THERAPEUTICS INC - ACLARIS ANNOUNCES REDUCTION IN
WORKFORCE
    * ACLARIS THERAPEUTICS INC - ACLARIS HAS APPROVED A PLAN TO
REDUCE
ITS WORKFORCE BY APPROXIMATELY 46%
    * ACLARIS THERAPEUTICS INC - ATI-1777 PHASE 2B TRIAL TOPLINE
DATA
ANTICIPATED IN JANUARY 2024
    * ACLARIS THERAPEUTICS INC - ACLARIS ANTICIPATES THIS
REDUCTION
WILL BEGIN IMMEDIATELY AND WILL BE SUBSTANTIALLY COMPLETE BY
JUNE 30, 2024
    * ACLARIS THERAPEUTICS INC - REASSESSING MOST EFFECTIVE
PATHWAY
FOR ATI-2138
    * ACLARIS THERAPEUTICS INC - INTENDS TO ACCELERATE
ADVANCEMENT OF
SEVERAL OF ITS DISCOVERY PROGRAMS EMERGING FROM KINECT DRUG
DISCOVERY PLATFORM
    * ACLARIS THERAPEUTICS INC -  NOW PLANS TO EXPLORE USE OF
ZUNSEMETINIB AS A POTENTIAL TREATMENT FOR PANCREATIC CANCER AND
METASTATIC BREAST CANCER
    * ACLARIS THERAPEUTICS INC - PLANS TO USE ATI-450 INSTEAD OF
ATI-2231, SECOND MK2 INHIBITOR, DUE TO ATI-450'S MORE ADVANCED
CLINICAL DEVELOPMENT PACKAGE

Source text for Eikon:  ID:nGNX4phkbz 
Further company coverage:  ACRS.O 

 ((Reuters.Briefs@thomsonreuters.com;))